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Abstract Severe psychotic disorders, which on their
own may be a risk factor for metabolic disorder and
cardiovascular illness, are clinically compounded by the
significant adverse side effects of antipsychotic medica-
tions. The majority of patients with severe psychotic
disorders (i.e., schizophrenia, bipolar disorder, mania,
and depression) must take antipsychotic medications to
treat their psychoses and, subsequently, will require
efficacious interventions to manage the metabolic con-
sequences of pharmacologic treatment to mitigate exces-
sive mortality associated with cardiovascular illness. We
have reviewed the metabolic consequences of antipsy-
chotic treatment and discussed pilot findings from a
new nonpharmacologic intervention study looking at
the clinical benefits of regular exercise as a management
tool for the cardiometabolic risk factors in a cohort with
severe mental illness.
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Introduction
Metabolic and Cardiovascular Disease in Severe Mental Illness
Of all the mental disorders, those that fall under the umbrella
of psychotic disorders are certainly the most disabling and
most difficult to manage. Severe psychiatric deficits, includ-
ing hallucinations, delusions, cognitive difficulties, and poor
social and occupational functioning, plus a debilitating course
of lifelong cognitive impairments are characteristic of patients
diagnosed with schizophrenia, severe bipolar disorder, and
chronic clinical depression [1]. These disorders are also char-
acterized by significantly decreased life expectancy with the
chief factors of this excess risk of death arising from cigarette
smoking, obesity, metabolic disorders associated with diabe-
tes, hypertension, and stroke [2, 3]. A recent survey of over
1000 subjects with psychotic disorders conducted in Australia
noted that over 75 % of all patients were overweight or obese,
20 % suffered from diabetes and hypertension, and over 50 %
of patients met criteria for metabolic syndrome, defined by a
combination of central obesity plus 2 or more of the following
risk factors: elevated HDL C levels, increased blood pressure,
increased blood glucose levels [4]. Other recent studies done
in South America and in Asia have reported that prior to
treatment, young patients may already be at a metabolic
disadvantage, with already higher than average rates of obe-
sity (21 %), hypertension (29 %), and smoking (26 %) and
significantly increased rates of diabetes (8 % vs 1 % in age-
matched controls) [5, 6]. These physical health deficits are
considerably exacerbated by the antipsychotic and antidepres-
sant medications required to treat their mental illnesses.
For many patients, reduction of dosing and/or tapering
off psychotropic medications is not clinically recommended,
given the seriousness of these mental disorders and the high
risk of relapse and significant self-harm and harm to others.
The long-term overall result is an approximate 20-year
D. J. Lang (*)
Department of Radiology, University of British Columbia,
Centre for Complex Disorders, British Columbia Mental Health
and Addictions Research Institute, CFRI Bldg, Rm. 3A-124,
938 West 28th Ave, BC Children’s Hospital Site,
Vancouver, BC, Canada V5Z 4H4
e-mail: dlang@mail.ubc.ca
A. M. Barr
Department of Pharmacology, British Columbia Mental Health and
Addictions Research Institute, Vancouver, BC, Canada V5Z 4H4
R. M. Procyshyn
Department of Psychiatry, British Columbia Mental Health and
Addictions Research Institute, Vancouver, BC, Canada V5Z 4H4
Curr Cardiovasc Risk Rep (2013) 7:283–287
DOI 10.1007/s12170-013-0321-1
reduction of lifespan from early death from cardiovascular
and metabolic disease [7]. Mortality rates are likely to be
similar in Canada and the US. Alternate non-pharmacologic
approaches and interventions for concurrent metabolic dis-
orders in severe mental illness are required to modify the
cardiometabolic sequelae of treatment to alleviate the bur-
den of mortality in this population.
Medication Treatment: Cardiovascular and Metabolic Effects
In the previous decade, increased rates of abdominal obesity,
dyslipidemia, hyperglycemia, and hypertension have been
observed in patients with psychotic disorders, all of which
are key risk factors for cardiometabolic disorders, such as
diabetes and cardiovascular disease [8, 9]. Patients presenting
with severe psychosis and schizophrenia spectrum disorders
are widely prescribed antipsychotic medications to manage
the symptoms of illness. There are an estimated 235,000
people with schizophrenia in Canada, with an economic im-
pact at over $6.85 billion annually [10]. The use of antipsy-
chotic drugs has increased dramatically in the past decade,
with the introduction of newer compounds with different side-
effect profiles, additional approved indications as well as
greater off-label use. For example, members of our group
have previously reported that antipsychotics were being used
off-label for a wide range of disorders, including bipolar,
depression, anxiety, and personality disorders in a large Ca-
nadian cohort [11]. We and others have reported that antipsy-
chotics are also being prescribed increasingly to nontraditional
populations such as children and adolescents.
The first generation antipsychotics (FGAs), or “typical”,
antipsychotic drugs were developed in the 1950s, and revolu-
tionized psychiatry. However, many patients remained resis-
tant or refractory to their clinical effects, and extended use
commonly resulted in severe neurological motor side-effects,
and subsequently fell out of favor [12, 13]. The second gener-
ation antipsychotics (SGAs) (also known as the “atypicals”),
developed in the 1990 and 2000s, represent compounds with
greater efficacy for refractory psychosis. While the SGAs
display much lower propensity to induce motor side-effects,
recent research has indicated that these drugs are commonly
associated with different but equally severe side-effects. All
antipsychotic medications are associated with higher rates of
sedation, sexual dysfunction, postural hypotension, cardiac
arrhythmia, and sudden cardiac death [13, 14]. Preclinical
animal studies have clearly shown that exposure to SGAs have
direct adverse effects on the cardiovascular system [15]. At this
time there is overwhelming evidence indicating that use of the
SGAs can result in severe metabolic disturbances that requires
much better clinical management than currently provided in
order to prevent unnecessary mortality [8, 16]. These effects
are so severe that the American Diabetes Association, the
American Psychiatric Association, the American Association
of Clinical Endocrinologists and the North American Associ-
ation for the Study of Obesity co-sponsored a Joint Consensus
Statement, providing guidelines for assessment of metabolic
risk for all patients being treated with atypical antipsychotics
[17].
Weight gain is the most common adverse effect among the
SGAs and some of the FGA. In a review of the literature,
Allison et al. [18] noted the following mean increases in
weight at 10 weeks of treatment with the SGAs: clozapine
4.45 kg, olanzapine 4.15 kg, chlorpromazine 2.58 kg, risper-
idone 2.10 kg, haloperidol (a FGA) 1.08 kg, and ziprasidone
0.04 kg. In another systematic review, increases in weight of
10 % or more associated with clozapine, olanzapine, and
risperidone were: 6 % at 8 weeks, 15 % at 10 weeks, and
27 %–60 % at 3–12 months [19]. These results have been
corroborated in several meta-analyses [20]. Our own observa-
tions in a cohort of drug-naïve first episode patients showed an
average weight gain of 1.8 kg in just 4 weeks of low dose
risperidone or quetiapine exposure (unpublished data). Con-
comitant dislipidemia has also been noted in those treated with
SGAs [21–23]. The SGA quetiapine is also often associated
with increased triglyceride levels [24].
Alarmingly, among patients with metabolic syndrome,
the relative risk for type II diabetes and coronary heart
disease (CHD) is 1.5–5 times that of the general population
[25]. Results from the Clinical Antipsychotic Trial of Inter-
vention Effectiveness (CATIE) study (a large multi-center
trial sponsored by NIMH) controlled for factors including
age, race and gender and observed that 42.7 % of patients
treated with atypicals had metabolic dysregulation. When
controlling for Body Mass Index (BMI), CATIE men were
85 % more likely, and CATIE women 137 % more, to have
metabolic syndrome than their control counterparts [26].
The greater risk for metabolic dysregulation associated with
SGAs may be independent of effects on body weight [27,
28]. It is therefore very likely that the SGAs exert effects on
glucose tolerance and insulin sensitivity that are indepen-
dent of (and not secondary to) weight gain.
Further evidence in support of this hypothesis comes
from reports that have detailed new-onset diabetes in the
absence of obesity or substantial weight gain in atypical
drug-treated patients [29]. Additionally, acute effects of
SGAs in normal subjects included glucose intolerance in
the absence of major weight gain [30]. Over 25 % of the
diabetic keto-acidosis and 15 % of new-onset hyperglyce-
mia cases were in atypical-treated patients who did not
experience weight gain or who had lost weight [29].
Management Strategies and Nonpharmacological
Interventions: Clinical Monitoring and Exercise
Despite incontrovertible evidence of increased cardiometabolic
risk in individuals with mental illness taking antipsychotic
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medication, metabolic screening practices are often incomplete
or inconsistent [31]. Unfortunately, patients with schizophrenia
are often at risk of receiving less optimal treatment for cardio-
vascular disease compared with other populations [32]. A re-
cent review by Mitchell and colleagues found that across 39
internationally published studies, rates of routine baseline met-
abolic screening was generally low, and above 50 % only for
blood pressure and triglycerides (59.9 %). Cholesterol was
measured in 41.5 %, glucose in 44.3 %, and weight in 47.9 %
of patients. Lipids and glycosylated haemoglobin (HbA1c)
were monitored in less than 25 % [31]. These data indicated
that in routine clinical practice, metabolic monitoring is
remarkably low in people prescribed antipsychotic med-
ications, despite the introduction of new monitoring
guidelines for this population [33]. The following mea-
surements were recommended in the development of
new guidelines (in order of frequency): fasting glucose,
body mass index, fasting triglycerides, fasting cholesterol,
waist, high-density lipoprotein/low-density lipoprotein, blood
pressure, and symptoms of diabetes [33]. In an ongoing study
that we are conducting in a cohort of treatment-resistant
chronic psychosis patients, we have observed that an addi-
tional measure of arterial stiffness based on aortic pulse wave
velocity offers a sensitive and effective tool for evaluating
cardiovascular disease risk in this population, and may be a
more rapid way of accurately assessing cardiovascular disease
risk (Phillips et al. submitted) [34].
In terms of additional interventions, most clinical guide-
lines recommended providing advice on physical activity,
diet, psycho-education of the patient (and family), treatment
of lipid abnormalities, treatment of diabetes, referral for advice
and treatment, and smoking cessation advice. While com-
mendable, the provision of advice alone does not ensure that
patients most in need of intervention actually receive any
appropriate intervention. Moreover, due to the physical and
psychological limitations of this population, physical activity,
or exercise interventions, which are likely to confer consider-
able health benefits with respect to moderating the metabolic
side-effects of medications, requires both a tailored exercise
prescription and ongoing clinical monitoring. Exercise bar-
riers for those with severe mental disorders generally include
lack of motivation, poor concentration, sedative effects of
medications, insufficient financial resources, and lack of ac-
cess to appropriate exercise programs [35].
It has been suggested that the beneficial effects of exer-
cise may be greatly under-appreciated and that the positive
effects of controlled exercise include not only improved
metabolic responses, but may also confer neuro-protection,
increased quality of life, and reduction in the severity of
psychopathological symptoms [36]. With respect to the
adverse metabolic effects of antipsychotic treatment, phys-
ical exercise can prevent or lessen cardiovascular disease
risk factors including elevated blood pressure, insulin
resistance, glucose intolerance, elevated blood triglycerides,
low high-density lipoprotein cholesterol levels, and obesity,
all of which are high in prevalence in psychosis patients
[37].
It is apparent that severe mental illnesses are diseases of
the brain, resulting in adverse clinical sequelae, such as
psychosis and cognitive dysfunction. Exercise may provide
direct benefit for these aspects of the illness as well. In this
regard, a recent review has highlighted the value of regular
exercise programs in schizophrenia patients with respect to
ameliorating the severity of psychosis [38••]. Clearly, for
those with severe mental illness, appropriate exercise offers
both physical and psychiatric benefits, and is thought to
exert a salutary effect on interacting networks mediating
metabolism, immuno-inflammatory function, and cellular
respiration for both body and brain [39]. The therapeutic
benefits of regular exercise in those with major depression is
well known [40], and is also believed to alleviate symptom
severity in schizophrenia patients [41]. Currently, there is a
paucity of research testing its effects on people seeking help
for mental health issues [42]. Moreover, it is generally
observed that compliance with prescribed exercise programs
is low [42]. It is likely that expecting people to exercise at
levels recommended by standard population guidelines may
be unrealistic given their struggle with mental health issues,
or that self-directed exercise is possible.
In an ongoing investigation our group is studying the
effects of a 12-week regular exercise intervention on physical
and mental health in chronic treatment-resistant psychosis
patients. Full cardiovascular fitness evaluations have so far
been conducted in a cohort of 17 chronic psychosis patients
(mean age 31.9 yrs) treated with high dose SGAs (Invited
Poster Symposium - International Congress of Schizophrenia
Research 2013, Orlando, Florida) [43•]. Individualized exer-
cise programs were tailored to patients based on their baseline
cardiorespiratory fitness and motor abilities. For this study,
fitness progress was closely monitored on a weekly basis over
the 12-week course of intervention. Full cardiorespiratory
fitness was re-assessed at 6 weeks and 12 weeks. It is well
known that low cardiovascular or cardiorespiratory fitness, as
assessed by V02 Max, is a key factor for coronary heart
disease. The mean cardiovascular capacity (V02 Max -
ml/kg/min) in this cohort at baseline was 19.8 ml/kg/min, far
below the expected healthy norms for this age cohort [44], and
was congruent with patients suffering from mild to moderate
heart failure [45]. The observation of lower than predicted V02
Max capacity has been observed in less severely ill schizo-
phrenia patients as well [46, 47]. Despite the presence of
SGAs, we, and others have measured improvements in V02
Max and blood pressure after just 6 to 12 weeks of regular
exercise at moderate exertion levels (55 %–70% of maximum
heart rate) [43•, 46]. Our own data have shown that after only
12weeks of regular exercise, patients were able to reduce their
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average body mass index (BMI) from a mean baseline BMI of
29.9 to a mean BMI of 27.1 12 weeks later [43•]. For this
cohort of severely ill patients, improvements in anxiety, de-
pression, and psychotic symptom severity were also observed
after completion of 12 weeks of regular exercise [43•].
These preliminary observations strongly suggest that even
for the most symptomatically severe and treatment refractory
patients, adjunct regular exercise offers significant benefits
with respect to lessening metabolic effects of antipsychotic
treatment. Moreover, the improvements in mood deficits and
cognitive deficits conferred by regular exercise can be attained
without further burden of anxiolytics, antidepressants, or
mood stabilizers. Given the positive effects of controlled
exercise to improve metabolic responses, provide neuro-
protection, increase quality of life, and reduce psychopatho-
logical symptoms, an individualized exercise prescription in
the context of a monitored exercise program is an optimal and
cost-effective method to manage the cardio-metabolic side
effects of medication and should be widely available to those
with severe mental illness.
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